HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: A replication study

Journal of Clinical Psychopharmacology

Volumn 29, Issue 1, 2009, Pages 16-20

  Mulder, Hans ^a,b   Cohen, Dan ^c,d   Scheffer, Hans ^e   Gispen De Wied, Christine ^f,g   Arends, Johan ^h   Wilmink, Frederik W ^h   Franke, Barbara ^e   Egberts, Antoine C G ^a,g  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Wilhelmina Ziekenhuis   (Netherlands)

^c Mental Health Services GGZ NHN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MEDICINES EVALUATION BOARD   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h Mental Health Services Drenthe   (Netherlands)

Author keywords

Antipsychotics; HTR2C; Metabolic syndrome; Schizophrenia

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE; NEUROLEPTIC AGENT; SEROTONIN 2C RECEPTOR;

ADULT; ALLELE; ARTICLE; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HTR2C GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; CROSS-SECTIONAL STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; META ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; METABOLIC SYNDROME X; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RECEPTOR, SEROTONIN, 5-HT2C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 62649090828     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181934462     Document Type: Article

References (20)

1. De Hert MA, Van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
2. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
3. de Leon J. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use. J Clin Psychopharmacol. 2008;28:125-131.
4. 2C receptor and antipsychotic-induced weight gain - mechanisms and genetics. J Psychopharmacol. 2006;20:15-18.
5. Mulder H, Franke B, van der-Beek van der AA, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol. 2007;27:338-343.
6. Mulder H, Franke B, van der-Beek van der AA, et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J. 2007;7:318-324.
7. Cohen D, Stolk RP, Grobbee DE, et al. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care. 2006;29:786-791.
8. Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry. 2001;62(suppl 7):11-21.
9. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-1428.
10. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363-365.
11. Pacey-Miller T, Henry R. Single-nucleotide polymorphism detection in plants using a single-stranded pyrosequencing protocol with a universal biotinylated primer. Anal Biochem. 2003;317:166-170.
12. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856-865.
13. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138:923-936.
14. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. 1998;316:1236-1238.
15. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet. 2005;366:1315-1323.
16. De Luca V, Mueller DJ, de Bartolomeis A, et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol. 2007;10:1-8.
17. 2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005;15:195-200.
18. 2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet. 2005;134:76-78.
19. 2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1021-1028.
20. 2C receptor and leptine gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry. 2008;192:424-428.